Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Aditya Bardia(Harvard University), Wells A. Messersmith(University of Colorado Cancer Center), Ebenezer A. Kio(Goshen Health), Jordan Berlin(Vanderbilt-Ingram Cancer Center), Linda T. Vahdat(Cornell University), Gregory A. Masters, R Moroose(Orlando Health), Alessandro D. Santin(Yale University), Kevin Kalinsky(Columbia University Irving Medical Center), Vincent J. Picozzi(Virginia Mason Medical Center), Joyce O’Shaughnessy(Texas Oncology), Jhanelle E. Gray(Moffitt Cancer Center), Takefumi Komiya(Parkview Health), Joshua M. Lang(University of Wisconsin Carbone Cancer Center), Jenny C. Chang(Houston Methodist), Alexander Starodub(Riverside Regional Medical Center), David M. Goldenberg(Gilead Sciences (United States)), Robert M. Sharkey(Gilead Sciences (United States)), Pius Maliakal(Gilead Sciences (United States)), Q. Hong(Immunomedics (United States)), William A. Wegener(Immunomedics (United States)), Trishna Goswami(Immunomedics (United States)), Allyson J. Ocean(Cornell University)
Cited by 364
Abstract
Related Papers
No related papers found
Powered by citation graph analysis